Construction of an HBV DNA vaccine by fusion of the GM-CSF gene to the HBV-S gene and examination of its immune effects in normal and HBV-transgenic mice

Vaccine

Volumn 28, Issue 26, 2010, Pages 4301-4307

  Qing, Yuling ^a   Chen, Min ^a   Zhao, Jiajiang ^a   Hu, Huaidong ^a   Xu, Hongmei ^a   Ling, Ning ^a   Peng, Mingli ^a   Ren, Hong ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

DNA Vaccine; GM CSF; HBsAg

Indexed keywords

ADJUVANT; COMPLEMENTARY DNA; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENE FUSION; HEPATITIS B; HUMORAL IMMUNITY; IMMUNIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; CYTOKINES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEPATITIS ANTIBODIES; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MALE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PLASMIDS; VACCINES, DNA;

EID: 77952882306     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.023     Document Type: Article

References (21)

1. Maynard J.E., Kane M.A., and Hadlert S.C. Global control of hepatitis B through vaccine. Rev Infect Dis 2 3 (1989) 574-575
2. Yuen M.F., and Lai C.L. Treatment of chronic hepatitis B. Lancet Infect Dis 1 4 (2001) 232-241
3. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 5102 (1993) 1745-1749
4. Srivastava I.K., and Liu M.A. Gene vaccine. Ann Intern Med 138 7 (2003) 550-559
5. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., et al. Direct gene transfer into mouse muscle in vivo. Science 247 4949 (1990) 1465-1468
6. Ogra P.L., Faden H.S., Abraham R., Duffy L.C., Sun M., and Minor P.D. Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. J Infect Dis 164 1 (1991) 191-194
7. Oka Y., Akbar S.M., Horiike N., Joko K., and Onji M. Mechanism and therapeutic potential of DNA-based immunization against the envelope proteins of hepatitis B virus in normal and transgenic mice. Immunology 103 1 (2001) 90-97
8. Tacket C.O., Roy M.J., Widera G., Swain W.F., Broome S., Edelman R., et al. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 17 22 (1999) 2826-2829
9. Scheerlinck J.Y. Genetic adjuvants for DNA vaccines. Vaccine 19 17-19 (2001) 2647-2656
10. Yoon H.A., Aleyas A.G., George J.A., Park S.O., Han Y.W., Lee J.H., et al. Cytokine GM-CSF genetic adjuvant facilitates prophylactic DNA vaccine against pseudorabies virus through enhanced immune responses. Microbiol Immunol 50 2 (2006) 83-92
11. Orson F.M., Kinsey B.M., Densmore C.L., Nguyen T., Wu Y., Mbawuike I.N., et al. Protection against influenza infection by cytokine-enhanced aerosol genetic immunization. J Gene Med 8 4 (2006) 488-497
12. Stagg J., Wu J.H., Bouganim N., and Galipeau J. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy. Cancer Res 64 24 (2004) 8795-8799
13. Thermet A., Rollier C., Zoulim F., Trepo C., and Cova L. Progress in DNA vaccine for prophylaxis and therapy of hepatitis B. Vaccine 21 7-8 (2003) 659-662
14. Xu R., Cai K., Zheng D., Ma H., Xu S., and Fan S.T. Molecular therapeutics of HBV. Curr Gene Ther 3 4 (2003) 341-355
15. Böcher W.O., Dekel B., Schwerin W., Geissler M., Hoffmann S., Rohwer A., et al. Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection. Eur J Immunol 31 7 (2001) 2071-2079
16. Mancini-Bourgine M., Fontaine H., Scott-Algara D., Pol S., Bréchot C., and Michel M.L. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 40 4 (2004) 874-882
17. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90 8 (1993) 3539-3543
18. Mévélec M.N., Bout D., Desolme B., Marchand H., Magné R., Bruneel O., et al. Evaluation of protective effect of DNA vaccination with genes encoding antigens GRA4 and SAG1 associated with GM-CSF plasmid, against acute, chronical and congenital toxoplasmosis in mice. Vaccine 23 36 (2005) 4489-4499
19. Sedegah M., Weiss W., Sacci Jr. J.B., Charoenvit Y., Hedstrom R., Gowda K., et al. Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J Immunol 164 11 (2000) 5905-5912
20. Kusakabe K., Xin K.Q., Katoh H., Sumino K., Hagiwara E., Kawamoto S., et al. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 164 6 (2000) 3102-3111
21. Barouch D.H., Santra S., Tenner-Racz K., Racz P., Kuroda M.J., Schmitz J.E., et al. Potent CD4+ T cell responses elicited by a bicistroni HIV-1 DNA Vaccine expressing gp120 and GM-CSF. J Immunol 168 2 (2002) 562-568